1,539 results on '"Rolfo, Christian"'
Search Results
2. Recommendations for reporting tissue and circulating tumour (ct)DNA next-generation sequencing results in non-small cell lung cancer
3. Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation
4. Validation of a multiomic model of plasma extracellular vesicle PD-L1 and radiomics for prediction of response to immunotherapy in NSCLC
5. CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial
6. Correction to: CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial
7. Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges
8. Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma
9. Standardized molecular pathology workflow for ctDNA-based ESR1 testing in HR+/HER2- metastatic breast cancer
10. Unveiling the impact of circulating tumor cells: Two decades of discovery and clinical advancements in solid tumors
11. Hypersensitivity Reactions to Selpercatinib Treatment With or Without Prior Immune Checkpoint Inhibitor Therapy in Patients With NSCLC in LIBRETTO-001.
12. Facing an un-met need in lung cancer screening: The never smokers
13. Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid TumorsEntrectinib in NTRK+ Solid Tumors: Updated Efficacy/Safety
14. Engineered extracellular vesicles for cancer drug delivery and therapeutics
15. Baseline extracellular vesicle miRNA-30c and autophagic CTCs predict chemoradiotherapy resistance and outcomes in patients with lung cancer
16. Applications and clinical trial landscape using Toll-like receptor agonists to reduce the toll of cancer
17. Genomic Landscape of Primary Resistance to Osimertinib Among Hispanic Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC): Results of an Observational Longitudinal Cohort Study
18. Clinical utility of Next Generation Sequencing of plasma cell-free DNA for the molecular profiling of patients with NSCLC at diagnosis and disease progression
19. Characteristics of Lung Cancer Patients With Asymptomatic or Undiagnosed SARS-CoV-2 Infections
20. Genomic profiling of tissue and blood predicts survival outcomes in patients with resected pleural mesothelioma
21. Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 TrialIntracranial Efficacy of Selpercatinib in RET Fusion+ NSCLC
22. Circulating epithelial cell as viral infection and tissue origin marker in patients with severe COVID-19
23. The educational contribution of the college of the European school of oncology (ESCO): A survey analysis of the first three years
24. Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study
25. Gene-network analysis predicts clinical response to immunotherapy in patients affected by NSCLC
26. Predictive Capability of PD-L1 Protein Expression for Patients With Advanced NSCLC: Any Differences Based on Histology?
27. Circulating tumor cells in cancer-risk populations as a cancer interception tool
28. Nitroglycerin Plus Whole Intracranial Radiation Therapy for Brain Metastases in Patients With Non-Small Cell Lung Cancer: A Randomized, Open-Label, Phase 2 Clinical Trial
29. Lung Cancer
30. Tumor Board and Molecular Tumor Board
31. Liquid Biopsy
32. Multi-cancer early detection (MCED) tests: prioritizing equity from bench to bedside
33. Supplementary Figure S3 from NPY Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer
34. Supplementary Materials and Methods S1 from NPY Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer
35. Supplementary Data S1 from NPY Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer
36. Supplementary Tables S1-S10 from NPY Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer
37. Engineered EVs for cancer drug delivery and therapeutics
38. The evolving role of liquid biopsy in lung cancer
39. Germline Predisposition and Copy Number Alteration in Pre-stage Lung Adenocarcinomas Presenting as Ground-Glass Nodules
40. Mechanisms of Resistance to First-Line Osimertinib in Hispanic Patients With EGFR Mutant Non-Small Cell Lung Cancer (FRESTON-CLICaP)
41. STK11 and KEAP1 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP)
42. NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types
43. Eight-Year Experience of the Certificate of Competence and Advanced Studies Program Organized by the European School of Oncology
44. EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment
45. Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer
46. Immunotherapy in Lung Cancer: Are the Promises of Long-Term Benefit Finally Met?
47. Lung Cancer and Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Identifying Important Knowledge Gaps for Investigation
48. ESO's career development program (2002-2021): Presentation and evaluation
49. Time-Dependent Effects of Clinical Interventions on SARS-CoV-2 Immunity in Patients with Lung Cancer.
50. Diagnosis and Management of Radiation Necrosis in Patients with Brain Metastases and Primary Tumors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.